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Edited by Gianni CesareniAbstract Homeodomain-interacting protein kinase 2 (HIPK2)
interacts with and phosphorylates various transcription factors
that are critical regulators of cell fate decisions and apoptosis
during development. Here we show that lysine 25 of HIPK2 is
the major sumoylation site, both in vitro and in vivo, and that
the sumoylation of this site occurs in a phosphorylation-
dependent manner. This became clear with the ﬁnding that ki-
nase-dead HIPK2 (K221R) could not be eﬃciently sumoylated
in vitro. The sumoylation of HIPK2 resulted in the disruption
of its interaction with a Groucho corepressor. Consequently,
sumoylation inhibited the regulatory activity of HIPK2 on the
Groucho-mediated repression of transcription, whereas not on
p53-mediated transactivation. These results suggest that phos-
phorylation-dependent sumoylation enables HIPK2 to drive dif-
ferent target gene transcription by means of diﬀerential
interactions with its binding partners.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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interaction1. Introduction
Homeodomain-interactingprotein kinase 2 (HIPK2),HIPK1,
and HIPK3 were initially identiﬁed via their abilities to interact
with Nkx1.2 homeoprotein [1]. The HIPKs constitute a novel
family of nuclear protein kinaseswhich localize in the subnuclear
compartments, and are well conserved in a variety of organisms
[1–3]. HIPK2 has multiple nuclear localization sequences, and is
predominantly localized in the nucleus, where HIPK2 regulates
a variety of transcription factors. The repressor function of the
NK-family homeoprotein is enhanced by the forced expression
of HIPK2, but the corepressor activity of Groucho is alleviatedAbbreviations: HIPK2, homeodomain-interacting protein kinase 2;
SUMO, small ubiquitin-like modiﬁer; Ubc9, ubiquitin-conjugating
enzyme 9; Myc-tag, Myc-epitope tag; PML, promyelocytic leukemia;
GST, glutathione S-transferase
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atively regulates POU domain transcription factor Brn3a-medi-
ated neuronal survival in the developing sensory ganglia [5].
Although the upstream extracellular stimuli associated with
HIPK2 activation remain poorly understood, the functional
importance of HIPK2 was estimated by means of its interacting
proteins and downstream phosphorylation targets. The induc-
tion of apoptosis has been attributed to the activity of HIPK2
due to its interactions with key regulatory proapoptotic cellular
proteins, including p53, CtBP and Sp100 [6–11]. These observa-
tions suggest the importance of HIPK2 activity in a variety of
cellular functions and developmental steps.
Small ubiquitin-like modiﬁer (SUMO) is the best-character-
ized member of a growing family of ubiquitin-related proteins.
SUMO is conjugated to target proteins using an enzyme conju-
gation system similar to that of ubiquitin [12,13]. SUMO-mod-
iﬁcation has been the focus of a great deal of attention, as
sumoylation participates in a number of cellular processes,
including nuclear transport, transcription regulation, apoptosis,
and protein stabilization [14,15]. The most prominent examples
are RanGAP1 and promyelocytic leukemia (PML). SUMO-
modiﬁcation of RanGAP1, which is essential for the transport
of proteins into the nucleus, targets it to the nuclear pore com-
plex via SUMO-speciﬁc binding with Ran-binding protein,
RanBP2. During mitosis, RanGAP1–RanBP2 complexes are
targeted to kinetochores in amicrotubule- and SUMO-1-depen-
dent fashion [16]. SUMO-modiﬁcation of PML is also required
for nuclear body formation and recruitment of other PML-
associated proteins. Many transcription factors are currently
identiﬁed as SUMO substrates, and in most cases modiﬁcation
with SUMO leads to transcription repression [15].
Here, we show that HIPK2 is modiﬁed by SUMO-1mainly at
lysine 25 in a full-length context, both in vitro and in vivo. This
SUMO-modiﬁcation is dependent on the phosphorylation of
HIPK2 by its own catalytic activity, and by other kinase(s).2. Materials and methods
2.1. Cell culture and transfection
U2OS and 293T cells were grown inDulbeccosmodiﬁed Eagles med-
ium, supplemented with 10% fetal bovine serum. For immunoblot anal-
ysis, 293T cells were seeded onto six-well plates, and DNA transfection
was carried out using theN,N-bis-(2-hydroxyethyl)-2-amino-ethanesul-
fonic acid-buﬀered saline version of the calcium phosphate procedure.blished by Elsevier B.V. All rights reserved.
Fig. 1. N-terminus of HIPK2 is a major site for modiﬁcation by
SUMO-1. (A) Myc-HIPK2 plasmids were transfected into U2OS cells
together with either GFP–SUMO-1 or GFP–SUMO-2, GFP–SUMO-
3 plasmids. SUMO-modiﬁed HIPK2 and unmodiﬁed HIPK2 were
detected with anti-Myc antibody (upper panel). The cell lysates were
also immunoprecipitated with anti-Myc antibody and the sumoylated
proteins were detected with anti-GFP antibody (lower panel). (B) Cells
were transfected with a series of HIPK2 deletion mutants and GFP–
SUMO-1 plasmid, and the sumoylation of each HIPK2 mutant was
observed by Western blotting with anti-Myc antibody. (C) A series of
HIPK2 deletion mutants was synthesized using in vitro translation,
and the products were subjected to in vitro sumoylation by the
addition of sumoylation reaction mix with (+) or without () GST–
SUMO(GG), followed by SDS–PAGE and Western blotting with anti-
Myc antibody.
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Various HIPK2 deletion constructs, EGFP–SUMO-1, were de-
scribed previously [1,4,17]. The Myc-SENP1 plasmid was constructed
by the insertion of cDNA PCR-ampliﬁed from human placenta cDNA
library (CLONTECH) into EcoRI and XbaI sites of pCS3MT. The
cDNAs for catalytic a subunit (clone ID: IRAT-48-E01) and regula-
tory b subunit (clone ID: IRAT-27-B01) of human protein phospha-
tase 2A were purchased from 21C Frontier Human Gene Bank
(Korea) and full-length coding regions were PCR-ampliﬁed and in-
serted into pEntr3C plasmid. The SUMO–HIPK2 plasmid encoding
amino acids 27–1189 of HIPK2 fused to SUMO-1 in its N-terminus
was constructed by the insertion of a PCR-ampliﬁed DNA fragment
for SUMO-1(aa 1–95) into the SacII site(aa 27 of HIPK2) of pEntr-
HIPK2. Point mutants of HIPK2 for sumoylation sites and Myc-
SENP1 C603A mutant were generated using the QuickChange
mutagenesis kit (Stratagene) according to the manufacturers recom-
mendations. Mutations were veriﬁed by DNA sequencing. Mutagene-
sis was done on the pEntr-derived HIPK2 plasmid, and Myc-tagged
and glutathione S-transferase (GST)-fusion HIPK2 expression plas-
mids were generated using Gateway Technology (Invitrogen).
2.3. Yeast two-hybrid interaction assay
The AH109 yeast strain was used as the host for a yeast two-hybrid
interaction assay. AH109 cells were transformed with various deletion
constructs of GAL4-DB/HIPK2 and GAL4-AD/mUbc9 plasmids.
Cells were spread onto synthetic drop-out agar plates lacking TL (tryp-
tophan, leucine) or TLH (tryptophan, leucine, and histidine). The spe-
ciﬁc interaction and binding strengths of the two fusion proteins were
veriﬁed by streaking several colonies onto agar plates lacking TL and
TLH.
2.4. In vitro SUMO-modiﬁcation
In vitro sumoylation assays were performed in a total volume of
20 ll in the presence of 50 mM Tris–HCl, pH 7.5, 2 mM DTT,
0.05% Tween-20, and 3 mM ATP at 37 C for the indicated times.
For the dephosphorylation and phosphorylation of HIPK2(1–629),
in vitro translated Myc-HIPK2(1–629) and puriﬁed GST–HIPK2 pro-
teins were pre-incubated with 2 units of calf intestinal alkaline phos-
phatase at 37 C for 30 min and 4 ll of rabbit reticulocyte lysates
(RRL) in the presence or absence of apyrase (Sigma) or 100 lM
ATPcS (Calbiochem), non-hydrolytic ATP competitor at 30 C for
1 h, respectively. Phosphorylated GST–HIPK2 was again subjected
to aﬃnity puriﬁcation in order to remove the ATPase (apyrase) or
ATPcS, followed by the in vitro SUMO-modiﬁcation reaction, as de-
scribed above.
2.5. In vitro pull-down assays
Myc-tagged HIPK2 deletion constructs were subjected to in vitro
translation using a TNT-coupled Reticulocyte Lysate System
(Promega). Pull-down assays were performed by incubating equal
amounts of GST or GST–ubiquitin-conjugating enzyme 9 (Ubc9) fu-
sion proteins immobilized onto glutathione–Sepharose beads with
the in vitro translated, 35S-labeled truncated form of HIPK2 as de-
scribed previously [4].3. Results
3.1. N-terminus of HIPK2 is a major site for modiﬁcation by
SUMO-1
We have previously shown that HIPK2 is covalently modi-
ﬁed by SUMO-1 [17]. In order to determine whether HIPK2
is modiﬁed by SUMO-2 or SUMO-3, which presumably per-
form diﬀerent physiological functions in the cell, Myc-HIPK2
expression plasmids were transfected into U2OS cells, together
with the expression plasmids GFP–SUMO-1, GFP–SUMO-2,
or GFP–SUMO-3. Immunoblot analysis revealed that an addi-
tional band of sumoylated HIPK2 was detected with the co-
expression of SUMO-1, but not with SUMO-2 or SUMO-3
(Fig. 1A, lanes 2–4). This indicates that HIPK2 is modiﬁed pri-
marily by SUMO-1 in U2OS cells.The identiﬁcation of HIPK2 sumoylation sites is critical to
understanding the role of sumoylation in the regulation of
HIPK2 activities. To this end, Myc-HIPK2(1–629) and Myc-
HIPK2(503–1189) expression plasmids were transfected into
the cells, together with SUMO-1 expression plasmids. The
amino-terminal HIPK2 was eﬃciently sumoylated (Fig. 1B,
lane 1), but only weak sumoylation was observed with the car-
boxy-terminal half of HIPK2(503–1189) containing the ID,
SRS and YH domains (data not shown). This indicates that
the major sumoylation site exists in the N-terminus of HIPK2.
Serial deletion analysis of the N-terminal HIPK2 revealed that
amino acids 503–629 and 1–24 were important for the sumoy-
lation of HIPK2 (Fig. 1B). Consistent with this result, the
deletion of amino acids 503–629 also abolished SUMO-modi-
ﬁcation of HIPK2 in vitro (Fig. 1C).
Twomotifs are required for the sumoylation of a protein, one
for binding to Ubc9, E2 SUMO-conjugating enzyme, and the
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hydrophobic amino acids, and X represents any amino acid)
[18,19]. HIPK2 contains three typical consensus sequences for
sumoylation: LK25VE, LK319PE and LK442TPD, and all these
residues are located in the N-terminus, including the kinase do-
main (Fig. 3A). As no consensus sequence for sumoylation has
been discovered in the 503–629 region of HIPK2, we attempted
to determine the interaction domains ofHIPK2withUbc9, via a
yeast two-hybrid assay.We constructed variousHIPK2deletion
mutants for fusion to the GAL4 DNA-binding domain, and
transformed an AH109 yeast strain with an Ubc9 expression
plasmid as a fusion to the GAL4 activation domain. Yeast
two-hybrid analysis revealed that two domains of HIPK2 were
responsible for its association with Ubc9, one for the kinase do-
main (amino acids 503–629), and the other for the SRS domain
(amino acids 860–1049) (Fig. 2A). Therefore, the loss of sumoy-
lation after the deletion to 503 residue is most likely caused by
the loss of interaction with Ubc9. AGST-pull down experiment
was also employed to conﬁrm the interaction domain of HIPK2Fig. 2. Ubc9 interaction domains of HIPK2. (A) Interaction domains
of HIPK2 with Ubc9. AH109 yeast cells were co-transformed with
GAL4-AD/Ubc9 and Gal4-DB/HIPK2 wild-type or various deletion
mutant plasmids. Yeast cells grown on synthetic drop-out plates
lacking tryptophan and leucine were streaked on the plates lacking
Trp, Leu, and Trp, Leu, His. A typical result is shown at the bottom.
Interaction domains of HIPK2 with Ubc9 are summarized on the right
of the schematics. +++ indicates strong interaction; + weak interac-
tion;  no interaction in this assay. (B) GST-pull down assay showing
direct interaction of HIPK2(1–629) with Ubc9. 35S-labeled HIPK2
deletion mutants were incubated with equal amounts of GST protein
and GST–Ubc9, and bound proteins were eluted and resolved in 8%
SDS–PAGE, and autoradiographed. The bindings of HIPK2 with
Ubc9 are summarized on the right of the schematics. I denotes 10% of
input, G and U indicate GST and GST–Ubc9, respectively.with Ubc9 (Fig. 2B). Although amino acids 503–629 were insuf-
ﬁcient to bind independently with Ubc9 in vitro, the deletion of
this region comparably impaired the binding of HIPK2 toUbc9
(Fig. 2B, lane 6). These results suggest that HIPK2 is mainly
modiﬁed by SUMO-1 at the N-terminus including the Ubc9-
interacting domain.3.2. Sumoylation of HIPK2 at lysine 25 in vitro and in vivo
Eﬃcient sumoylation of the N-terminus of HIPK2 both in
vivo and in vitro led us to analyze three typical consensus se-
quences for sumoylation, all of which are located in the ex-
treme N-terminus and the kinase domain (Fig. 3A), and well
conserved between HIPKs (data not shown). Lysine-to-argi-
nine substitution mutants were generated on a background
of Myc-HIPK2(1–629) by site-directed mutagenesis, and in vi-
tro translated wild-type and point mutants were subjected to in
vitro sumoylation. The kinase-dead K221R mutant was also
included in in vitro sumoylation to see whether the catalytic
activity of HIPK2 aﬀects its own sumoylation. Two slowly
migrating bands were observed with wild-type HIPK2(1–
629), indicating that at least two sites of HIPK2 were eﬃciently
sumoylated (Fig. 3B, lane 2). The sumoylated bands disap-
peared almost completely after the mutation of lysine 25 to
arginine (lane 4), and double or triple mutants containing
the K25R mutation exhibited no detectable SUMO-modiﬁed
HIPK2 (lanes 12, 14 and 18). These results indicate that the ly-
sine 25 residue is the major site for the SUMO-modiﬁcation of
HIPK2. This ﬁnding is consistent with the data recently pub-
lished [20]. The mutation of the lysine 442 residue did not aﬀect
the sumoylation of HIPK2(1–629) (lane 10). The kinase-dead
K221R mutant showed that sumoylation was markedly re-
duced, and a portion of the unmodiﬁed HIPK2 was increased,
as compared with that of wild-type HIPK2. This result sug-
gests that catalytic activity is required for the eﬃcient sumoy-
lation of HIPK2. The substitution of lysine 319 with arginine
resulted in reduced sumoylation, which is probably attribut-
able to the reduced catalytic activities of the K319R mutant,
as in the case of the kinase-dead K221R mutant, because the
migrations of K221R and K319R mutants were faster than
that of the wild-type (lanes 5–8), and also that K221 and
K319 are conserved amino acids of the ATP-binding pocket.
It remains unclear as to which amino acid comprises the sec-
ondary site for the sumoylation of N-terminal HIPK2 in vitro.
The sumoylation of the mutant HIPK2 was also tested in the
cultured cells by cotransfection of wild-type or mutant plas-
mids with a GFP–SUMO-1 expression plasmid, followed by
Western analysis with anti-Myc antibody. Only one sumoy-
lated HIPK2 was observed in U2OS cells (Fig. 3C). In a ﬁnd-
ing consistent with the in vitro data, the K25R mutant was not
sumoylated at all (lane 2), whereas the K442R mutant was
sumoylated at the same level as was wild-type HIPK2 in cul-
tured cells (lane 5). However, unlike in vitro data, the
K221R and K319R mutants exhibited no obvious changes
with regard to HIPK2 sumoylation (lanes 3 and 4). These re-
sults implied that whereas sumoylation of kinase-dead HIPK2
is impaired in vitro, in cultured cells phosphorylation of
kinase-dead HIPK2 by endogenous HIPK2 or by other ki-
nase(s) probably helped sumoylation of these mutants (see be-
low). We also examined the sumoylation of lysine 25 in the
full-length HIPK2 context. Cells were transfected with
wild-type Myc-HIPK2(1–1189) and Myc-HIPK2(K25R) mu-
Fig. 3. Sumoylation of HIPK2 at lysine 25 residue in vitro and in vivo. (A) The schematics of HIPK2 showing the positions of SUMO-1 consensus
sequences. These SUMO-1 consensus sequences are conserved between HIPK1, HIPK2 and HIPK3. (B) In vitro SUMO-modiﬁcation of the
indicated HIPK2(1–629) wild-type and point mutants with (+) or without () addition of a SUMO reaction mix. In vitro translated Myc-tagged
HIPK2 was subjected to in vitro sumoylation and the products were separated on 8% SDS–PAGE, followed by Western blotting with anti-Myc
antibody. (C) U2OS cells were transfected with the indicated wild-type or point mutants together with GFP–SUMO-1 expression plasmids. The cell
lysates were analyzed by Western blotting with anti-Myc antibody. (D) Full-length Myc-HIPK2 and Myc-HIPK2(K25R) plasmids were transfected
into U2OS cells, along with a GFP–SUMO-1 plasmid. The SUMO-modiﬁcations of HIPK2 and the K25R mutant in cultured cells were detected by
Western blotting with anti-Myc antibody. (E) NIH3T3 cells were transfected with Myc-HIPK2(1–629) or Myc-SENP1 C603A expression plasmid
together with GFP–SUMO-1 expression plasmid, and treated with 40 nM Okadaic acid for 12 h before Western blotting using anti-Myc antibody.
(F) The Myc-HIPK2(1–629) or Myc-SENP1 C603A mutant plasmid and GFP–SUMO-1 plasmid were transfected into NIH3T3 cells together with
or without both catalytic and regulatory subunits of protein phosphatase 2A as indicated. The sumoylations of proteins were detected with Western
blotting using anti-Myc antibody.
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sumoylation was visualized by Western blotting with anti-
Myc antibody. As shown in Fig. 3D, the K25R mutation al-
most abolished sumoylation of full-length HIPK2. These re-
sults strongly indicate that the lysine 25 residue of HIPK2 is
the major site for SUMO-modiﬁcation, in a full-length con-
text, both in vitro and in cultured cells. To ascertain the phos-
phorylation-dependent sumoylation of HIPK2 in cultured
cells, we performed two experiments of treatment of cells with
Okadaic acid, a serine/threonine phosphatase inhibitor and
coexpression of protein phosphatase 2A (PP2A). Treatment
of transfected cells with Okadaic acid and coexpression of both
catalytic and regulatory subunits of PP2A increased and de-
creased sumoylation of HIPK2, respectively (Fig. 3E, lane 2
and Fig. 3F, lane 2). However, the sumoylations of SENP1
C603A mutant and Sp100 (data not shown) were not changed
(Fig. 3E and F), indicating that the changes of sumoylation le-
vel of HIPK2 were caused by phosphorylation or dephospho-rylation of HIPK2, not by global or non-speciﬁc eﬀects of
phosphatase inhibitor or PP2A overexpression on the cellular
sumoylation machinery.
3.3. Phosphorylation-dependent sumoylation of lysine 25
As described above, the kinase-dead form of HIPK2 was not
eﬃciently sumoylated in vitro (Fig. 3B), so we reasoned that
phosphorylation of HIPK2 may be prerequisite for its sumoy-
lation. In an attempt to better understand phosphorylation-
dependent sumoylation, the wild-type and kinase-dead mutant
GST–HIPK2(1–629) were expressed in Escherichia coli, which
contains no upstream kinase for HIPK2. They were then aﬃn-
ity puriﬁed, and subjected to in vitro SUMO-modiﬁcation
reactions. The sumoylation of wild-type HIPK2 increased in
an incubation time-dependent manner, but the sumoylation
of the K221R mutant did not, indicating the phosphoryla-
tion-dependent sumoylation of the lysine 25 of HIPK2 (Fig.
4A). It should be noted that the sumoylation of GST–HIPK2
Fig. 4. Phosphorylation-dependent sumoylation of HIPK2 in vitro.
(A) GST–HIPK2(1–629) and kinase-dead mutant GST–
HIPK2(K221R) were expressed and aﬃnity puriﬁed from E. coli
BL21(DE3), and subjected to in vitro sumoylation with (+) or without
() the addition of a SUMO reaction mix. Reactions were continued
for the times indicated, and products were resolved on 8% SDS–
PAGE, followed by Western blotting with anti-HIPK2 antibody. (B)
For the phosphorylation of wild-type and mutant GST–HIPK2(1–
629), puriﬁed GST–HIPK2 and GST–HIPK2(K221R) mutants were
pre-incubated with 4 ll of RRL in the presence or absence of apyrase
(ATPase, Sigma) or ATPcS (Calbiochem) at 30 C for 1 h. Phosphor-
ylated GST–HIPK2 was again subjected to aﬃnity puriﬁcation for the
removal of ATPase or ATPcS, followed by in vitro SUMO-modiﬁ-
cation reaction, as described above. Sumoylated GST–HIPK2 was
detected by Western blotting with anti-HIPK2 antibody. (C) For the
dephosphorylation of Myc-HIPK2(1–629), in vitro translated Myc-
HIPK2 was pre-incubated with 2 units of calf intestinal alkaline
phosphatase at 30 C for 30 min. The same reaction mixes were then
allowed to incubate, either with (+) or without () the addition of
SUMO reaction mix for the times indicated. Sumoylated HIPK2(1–
629) proteins were detected by Western blotting with anti-Myc
antibody.
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translated Myc-HIPK2, under the same reaction conditions
(compare Fig. 3B, lane 2 with Fig. 4A, lane 4). Therefore, it
was speculated that Myc-HIPK2 might be phosphorylated
by other kinase(s) during in vitro translation, and that phos-
phorylated HIPK2 might be a better target for SUMO-modi-
ﬁcation than unphosphorylated HIPK2. To test this
hypothesis, puriﬁed GST–HIPK2 and K221R mutants were
pre-incubated with RRL in the presence or absence of ATPase
or ATPcS, which might block phosphorylation. GST–HIPKs
were aﬃnity-puriﬁed again in order to remove ATPase or
ATPcS, and subjected to in vitro sumoylation reactions. The
sumoylation of puriﬁed GST–HIPK2 signiﬁcantly increased
as a result of the pre-incubation of GST–HIPK2 with RRL
(Fig. 4B, lane 3), which had been completely blocked by the
treatments of ATPase and ATPcS (lanes 4 and 5). However,the incubation of HIPK2(K221R) mutant with RRL resulted
in a slight increase in HIPK2(K221R) sumoylation (lane 8).
In a converse experiment, the sumoylation of in vitro trans-
lated Myc-HIPK2 decreased due to pre-treatment with phos-
phatase prior to the in vitro sumoylation reactions (Fig. 4C,
lanes 3, 6, and 9). Collectively, it was concluded that both
the auto-phosphorylation of HIPK2 and the phosphorylation
of HIPK2 by other kinase(s) are required for the eﬃcient
sumoylation of HIPK2 in vitro.3.4. Diﬀerential interactions of SUMO-modiﬁed HIPK2 at
lysine 25
To understand the functional role of HIPK2 sumoylation at
lysine 25, we investigated its eﬀects on the localization, stabil-
ity, and diﬀerential interactions of HIPK2. Immunostaining of
U2OS cells transfected with the wild-type and K25R mutants
revealed that both proteins were localized in nuclear dots,
and that the level of both proteins was almost identical after
treatment with cycloheximide (data not shown). We demon-
strated previously that HIPK2 interacts with the Groucho
corepressor, and regulates their transcriptional activity
through phosphorylation [4]. To examine whether HIPK2
sumoylation aﬀects its binding to this protein, cell lysates con-
taining unmodiﬁed and SUMO-modiﬁed full-length HIPK2
were incubated with the same amounts of GST–Ubc9 and
GST–GRO, and the bound HIPK2 was eluted and analyzed
with Western blotting using anti-Myc antibody. Both unmod-
iﬁed and SUMO-modiﬁed HIPK2 were bound to GST–Ubc9,
but only unmodiﬁed HIPK2 was observed to interact with
GST–GRO (Fig. 5A, lane 4). To rule out the possibility that
the sumoylated HIPK2 is desumoylated by endogenous
SUMO proteases during the incubation of cell lysates with
GST-fusion proteins, and to conﬁrm the diﬀerential interac-
tions of sumoylated HIPK2 at lysine 25, we constructed a plas-
mid encoding SUMO–HIPK2 fusion protein, in which the
SUMO moiety was fused in frame to the sumoylation site of
HIPK2 (Fig. 5B). A GST-pull down experiment revealed that
GST–p53 bound to both wild-type HIPK2 and SUMO–
HIPK2 fusion protein. However, the interaction of SUMO–
HIPK2 fusion protein with GST–Groucho was greatly reduced
whereas wild-type HIPK2 interacted well with GST–Groucho
(Fig. 5C). As could be expected, the degree of Groucho phos-
phorylation by HIPK2 was also reduced when Groucho was
incubated with fully sumoylated HIPK2, which had been pre-
pared via in vitro sumoylation of the in vitro translated HIPK2
(Fig. 5D, lanes 3 and 6). This result suggests that the sumoyla-
tion of HIPK2 disrupts its interaction with Groucho, a phos-
phorylation target. Furthermore, the eﬀects of HIPK2
sumoylation on the Groucho-mediated transcriptional repres-
sion were studied with a transient transcription assay. The
repressor activity of GAL4–Groucho was alleviated by the
expression of wild-type HIPK2, as was previously described
[4], but additional SUMO-1 expression reversed the function
of HIPK2 on the transcriptional activity of Groucho (Fig.
5E, lane 5). In contrast, the HIPK2(K25R) mutant still exhib-
ited a de-repression of Groucho-mediated transcription, after
the SUMO-1 expression (Fig. 5E, lane 7). These results were
also observed in the transcription assay with NK-3 promoter,
a natural target of Groucho corepressor [4], as a reporter (Fig.
5E, lanes 8–13). The same approach was taken with p53, which
is able to interact with SUMO-modiﬁed HIPK2, as well as
Fig. 5. Diﬀerential interactions of sumoylated HIPK2 with Groucho and p53. (A) Cell lysates, prepared from NIH3T3 cells transfected with Myc-
HIPK2 and GFP–SUMO-1 expression plasmids, were incubated for 2 h at 4 C with equal amounts (1 lg) of GST, GST–Ubc9 and GST–GRO,
which were immobilized on glutathione–Sepharose beads. The beads were washed ﬁve times with washing buﬀer, and the bound proteins were
separated on 8% SDS–PAGE, followed by Western blotting with anti-Myc antibody. (B) Schematics of wild-type HIPK2 and SUMO–HIPK2
encoding SUMO–HIPK2 fusion protein, in which amino acids 1–95 of SUMO-1 are fused in frame to amino acids 27-1189 of HIPK2. (C) In vitro
translated HIPK2(K221R) and SUMO–HIPK2(K221R) fusion proteins were incubated with equal amounts (1 lg) of GST, GST–p53, and GST–
GRO, and the bound proteins were detected with anti-Myc antibody. H and S denote HIPK2(K221R) and SUMO–HIPK2(K221R) fusion protein,
respectively. (D) In vitro translated Myc-HIPK2(1–629) was immunoprecipitated with anti-Myc antibody, and the precipitates were subjected to in
vitro sumoylation for 30 min (lanes 2 and 5) and 90 min (lanes 3 and 6). The sumoylated HIPK2 was used in an IP-kinase assay in the presence of
0.5 lg of GST–GRO(1–333) as a substrate. The kinase reaction was continued for 30 min at 30 C, and stopped by the addition of 2X sample buﬀer.
The products were separated on 8% SDS–PAGE, dried and autoradiographed (right panel, lanes 4–6). The degree of HIPK2 sumoylation was
checked by Western blotting of the immunoprecipitates with anti-Myc antibody (left panel, lanes 1–3). (E) Myc-HIPK2 or Myc-HIPK2(K25R)
plasmids and GAL4–GRO, G5-SVEn-luc reporter plasmids were transfected into U2OS cells, together with or without GFP–SUMO-1 expression
plasmids. C2C12 cells were used for transcription assay with reporter plasmid containing NK-3 promoter (lanes 8–13). A p53 expression plasmid and
a p53RE-luc reporter plasmid were used in the experiments shown on the right panel (lanes 14–20). Thirty-six hours after transfection, luciferase
activity was measured using the Luciferase Reporter Assay System (Promega). Transfection eﬃciency was normalized by the expression of b-
galactosidase. The same experiments were repeated at least three times.
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iated transcription aﬀected by neither the mutation of lysine 25
nor the additional SUMO-1 expression (Fig. 5E, lanes 14–20).
These results strongly indicate that diﬀerential interactions of
HIPK2 with its binding partners could be achieved by
SUMO-modiﬁcation, which allows HIPK2 to change its mode
of interaction with its diverse binding partners.4. Discussion
In this report, we identiﬁed the lysine 25 of HIPK2 as a ma-
jor sumoylation site, both in vitro and in vivo, in the context offull-length HIPK2. Phosphorylation of HIPK2 is required for
the eﬃcient sumoylation of K25. Crosstalk between post-
translational modiﬁcations of phosphorylation and sumoyla-
tion begin to be uncovered. The phosphorylation of the
PML through p38 mitogen-activated protein (MAP) kinase
pathway is associated with increased sumoylation of PML,
and increased PML-mediated apoptosis [21]. The phosphory-
lation of the serine 303 of heat shock factor 1 (HSF1) by heat
shock-inducible kinase(s) is a prerequisite for the eﬃcient
sumoylation of HSF1 [22,23]. On the other hand, phosphory-
lation can also negatively regulate the sumoylation of target
proteins. Phosphorylation of the serine 20 of p53 and the ser-
ine 383 of Elk-1 by DNA damage-inducible kinase(s) and the
K.S. Sung et al. / FEBS Letters 579 (2005) 3001–3008 3007ERK pathway, respectively, result in the abolition of each pro-
teins sumoylation [24,25]. Catalytic inactive mutant
HIPK2(K221R) puriﬁed from E. coli, in which no upstream ki-
nase against HIPK2 exists, proved to be a poor substrate for
the SUMO-modiﬁcation system in vitro. However, catalyti-
cally active HIPK2 was eﬃciently sumoylated, and modiﬁca-
tion was further increased by the incubation of puriﬁed
protein with RRL (Fig. 4), suggesting that both the autophos-
phorylation of HIPK2 and phosphorylation by other kinase(s)
participates in the eﬃcient sumoylation of HIPK2. Recently, it
has been demonstrated that HIPK2 play a role in the Wnt-in-
duced Myb degradation pathway in hematopoietic cells that
involves TAK and NLK kinases [26]. Thus, identiﬁcation of
upstream kinases and the phosphorylation sites that are
responsible for increased sumoylation would provide impor-
tant clues about which signaling pathways are involved in
the phosphorylation-dependent sumoylation of HIPK2.
The role of phosphorylation in ubiquitin-mediated protein
degradation has been well established. Ubiquitin E3 ligases
speciﬁcally recognize phosphorylated target proteins [27].
The switch between the ubiquitination and the sumoylation
mode might be regulated by phosphorylation, such that the
unphosphorylated IBa favors the SUMO-modiﬁcation in the
NF-jB pathway, whereas phosphorylation triggers the ubiqui-
tination and the IjBa degradation [28,29]. The opposite could
be speculated in the case of HIPK2. Endogenous HIPK2 was
hardly detected, which was probably due to the continuous
degradation of HIPK2, as in the case of p53. UV-irradiation
caused stabilization of HIPK2, and consequently enhanced
phosphorylation of p53 at serine 46 by HIPK2, in a time-
dependent manner [6,7]. Thus it is conceivable that under-
phosphorylated or inactive HIPK2 are targets of the
ubiquitin-mediated proteolysis system in the resting cells,
whereas the activation of HIPK2 by signaling cues renders
its escape from degradation, and favors SUMO-modiﬁcation.
Stabilized HIPK2, in turn, may facilitate p53-mediated apop-
tosis by enhancing p53 activity through colocalization with,
and phosphorylation of p53. In the future, it would be interest-
ing to study the molecular mechanisms which regulate the bal-
ance between SUMO-modiﬁcation and the ubiquitination of
HIPK2, as this would clearly provide a better understanding
of the induction of p53-mediated apoptosis upon the signaling
pathways through HIPK2.
Acknowledgments: We thank Chin-ha Chung (Seoul National Univer-
sity, Seoul, Korea) for providing us with the pET-Ubc9 plasmid. We
also thank Ronald T. Hay (University of St. Andrews, UK) for giving
us the GST–SAE2/SAE1 plasmid. This work was supported by Grant
R01-2002-000-00373-0, from the Basic Research Program of the Korea
Science & Engineering Foundation to C.Y.C.References
[1] Kim, Y.H., Choi, C.Y., Lee, S.-J., Conti, M.A. and Kim, Y.
(1998) Homeodomain-interacting protein kinases, a novel family
of co-repressors for homeodomain transcription factors. J. Biol.
Chem. 273, 25875–25879.
[2] Moilanen, A.M., Karvonen, U., Poukka, H., Janne, O.A. and
Palvimo, J.J. (1998) Activation of androgen receptor function by
a novel nuclear protein kinase. Mol. Biol. Cell 9, 2527–2543.
[3] Begley, D.A., Berkenpas, M.B., Sampson, K.E. and Abraham, I.
(1997) Identiﬁcation and sequence of human PKY, a putative
kinase with increased expression in multidrug-resistant cells, with
homology to yeast protein kinase Yak1. Gene 200, 35–43.[4] Choi, C.Y., Kim, Y.H., Kwon, H.J. and Kim, Y. (1999) The
homeodomain protein NK-3 recruits Groucho and a histone
deacetylase complex to repress transcription. J. Biol. Chem. 274,
33194–33197.
[5] Wiggins, A.K., Wei, G., Doxakis, E., Wong, C., Tang, A.A.,
Zang, K., Luo, E.J., Neve, R.L., Reichardt, L.F. and Huang,
E.J. (2004) Interaction of Brn3a and HIPK2 mediates transcrip-
tional repression of sensory neuron survival. J. Cell. Biol. 167,
257–267.
[6] DOrazi, G., Cecchinelli, B., Bruno, T., Manni, I., Higashimoto,
Y., Saito, S., Gostissa, M., Coen, S., Marchetti, A., Del Sal, G.,
Piaggio, G., Fanciulli, M., Appella, E. and Soddu, S. (2002)
Homeodomain-interacting protein kinase-2 phosphorylates p53 at
Ser 46 and mediates apoptosis. Nat. Cell Biol. 4, 11–19.
[7] Hofmann, T.G., Moller, A., Sirma, H., Zentgraf, H., Taya, Y.,
Droge, W., Will, H. and Schmitz, M.L. (2002) Regulation of p53
activity by its interaction with homeodomain-interacting protein
kinase-2. Nat. Cell Biol. 4, 1–10.
[8] Moller, A., Sirma, H., Hofmann, T.G., Rueﬀer, S., Klimczak,
E., Droge, W., Will, H. and Schmitz, M.L. (2003) PML is
required for homeodomain-interacting protein kinase 2
(HIPK2)-mediated p53 phosphorylation and cell cycle arrest
but is dispensable for the formation of HIPK domains. Cancer
Res. 63, 4310–4314.
[9] Di Stefano, V., Rinaldo, C., Sacchi, A., Soddu, S. and DOrazi, G.
(2004) Homeodomain-interacting protein kinase-2 activity and
p53 phosphorylation are critical events for cisplatin-mediated
apoptosis. Exp. Cell Res. 293, 311–320.
[10] Zhang, Q., Yoshimatsu, Y., Hildebrand, J., Frisch, S.M. and
Goodman, R.H. (2003) Homeodomain interacting protein kinase
2 promotes apoptosis by downregulating the transcriptional
corepressor CtBP. Cell 115, 177–186.
[11] Mo¨ller, A., Sirma, H., Hofmann, T.G., Staege, H., Gresko, E.,
Ludi, K.S., Klimczak, E., Droge, W., Will, H. and Schmitz, M.L.
(2003) Sp100 is important for the stimulatory eﬀect of homeodo-
main-interacting protein kinase-2 on p53-dependent gene expres-
sion. Oncogene 22, 8731–8737.
[12] Muller, S., Ledl, A. and Schmidt, D. (2004) SUMO: a regulator of
gene expression and genome integrity. Oncogene 23, 1998–2008.
[13] Seeler, J.S. and Dejean, A. (2003) Nuclear and unclear functions
of SUMO. Nat. Rev. Mol. Cell. Biol. 4, 690–699.
[14] Schwartz, D.C. and Hochstrasser, M. (2003) A superfamily of
protein tags: ubiquitin, SUMO and related modiﬁers. Trends
Biochem. Sci. 28, 321–328.
[15] Gill, G. (2003) Post-translational modiﬁcation by the small
ubiquitin-related modiﬁer SUMO has big eﬀects on transcription
factor activity. Curr. Opin. Genet. Dev. 13, 108–113.
[16] Joseph, J., Liu, S.T., Jablonski, S.A., Yen, T.J. and Dasso, M.
(2004) The RanGAP1-RanBP2 complex is essential for micro-
tubule-kinetochore interactions in vivo. Curr. Biol. 14, 611–
617.
[17] Kim, Y.H., Choi, C.Y. and Kim, Y. (1999) Covalent modiﬁcation
of the homeodomain-interacting protein kinase 2 (HIPK2) by the
ubiquitin-like protein SUMO-1. Proc. Natl. Acad. Sci. USA 96,
12350–12355.
[18] Melchior, F., Schergaut, M. and Pichler, A. (2003) SUMO:
ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 28,
612–618.
[19] Kim, K.I., Baek, S.H. and Chung, C.H. (2002) Versatile protein
tag, SUMO: its enzymology and biological function. J. Cell.
Physiol. 191, 257–268.
[20] Gresko, E., Mo¨ller, A., Roscic, A. and Schmitz, M.L. (2005)
Covalent modiﬁcation of human homeodomain interacting pro-
tein kinase 2 by SUMO-1 at lysine 25 aﬀects its stability. Biochem.
Biophys. Res. Commun. 329, 1293–1299.
[21] Hayakawa, F. and Privalsky, M.L. (2004) Phosphorylation of
PML by mitogen-activated protein kinases plays a key role in
arsenic trioxide-mediated apoptosis. Cancer Cell 5, 389–401.
[22] Hietakangas, V., Ahlskog, J.K., Jakobsson, A.M., Hellesuo, M.,
Sahlberg, N.M., Holmberg, C.I., Mikhailov, A., Palvimo, J.J.,
Pirkkala, L. and Sistonen, L. (2003) Phosphorylation of serine 303
is a prerequisite for the stress-inducible SUMO modiﬁcation of
heat shock factor 1. Mol. Cell. Biol. 23, 2953–2968.
[23] Hilgarth, R.S., Hong, Y., Park-Sarge, O.K. and Sarge, K.D.
(2003) Insights into the regulation of heat shock transcription
3008 K.S. Sung et al. / FEBS Letters 579 (2005) 3001–3008factor 1 SUMO-1 modiﬁcation. Biochem. Biophys. Res. Com-
mun. 303, 196–200.
[24] Lin, J.Y., Ohshima, T. and Shimotohno, K. (2004) Association of
Ubc9, an E2 ligase for SUMO conjugation, with p53 is regulated
by phosphorylation of p53. FEBS Lett. 573, 15–18.
[25] Yang, S.H., Jaﬀray, E., Hay, R.T. and Sharrocks, A.D. (2003)
Dynamic interplay of the SUMO and ERK pathways in regulat-
ing Elk-1 transcriptional activity. Mol. Cell 12, 63–74.
[26] Kanei-Ishii, C., Ninomiya-Tsuji, J., Tanikawa, J., Nomura, T.,
Ishitani, T., Kishida, S., Kokura, K., Kurahashi, T., Ichikawa-
Iwata, E., Kim, Y., Matsumoto, K. and Ishii, S. (2004) Wnt-1signal induces phosphorylation and degradation of c-Myb protein
via TAK1, HIPK2, and NLK. Genes Dev. 18, 816–829.
[27] Busino, L., Chiesa, M., Draetta, G.F. and Donzelli, M. (2004)
Cdc25A phosphatase: combinatorial phosphorylation, ubiquity-
lation and proteolysis. Oncogene 23, 2050–2056.
[28] Desterro, J.M., Rodriguez, M.S. and Hay, R.T. (2000) Regulation
of transcription factors by protein degradation. Cell Mol. Life Sci.
57, 1207–1219.
[29] Desterro, J.M., Rodriguez, M.S. and Hay, R.T. (1998) SUMO-1
modiﬁcation of IkappaBalpha inhibits NF-kappaB activation.
Mol. Cell 2, 233–239.
